Next Article in Journal
Genetic Basis of the Epidemiological Features and Clinical Significance of Renal Hypouricemia
Previous Article in Journal
Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis
Previous Article in Special Issue
Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates

RNA Modification in Inflammatory Bowel Diseases

Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Department of Gastrointestinal Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Kinshu-kai Medical Corporation, Osaka 558-0011, Japan
Food and Life-Science Laboratory, Prophoenix Division, IDEA Consultants, Inc., Osaka 559-8519, Japan
Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Frederikskaj 10B, 2. (Building C), 2450 Copenhagen SV, Denmark
Department of Clinical and Molecular Medicine, University of Rome “Sapienza,” Santo Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
Author to whom correspondence should be addressed.
Academic Editor: Ferenc Sipos
Biomedicines 2022, 10(7), 1695;
Received: 14 June 2022 / Revised: 7 July 2022 / Accepted: 8 July 2022 / Published: 13 July 2022
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa, which is caused by a combination of factors. These include genetic and epigenetic alterations, environmental influence, microorganism interactions, and immune conditions. Some populations with IBD show a cancer-prone phenotype. Recent studies have provided insight into the involvement of RNA modifications in the specific pathogenesis of IBD through regulation of RNA biology in epithelial and immune cells. Studies of several RNA modification-targeting reagents have shown preferable outcomes in patients with colitis. Here, we note a new awareness of RNA modification in the targeting of IBD and related diseases, which will contribute to early diagnosis, disease monitoring, and possible control by innovative therapeutic approaches. View Full-Text
Keywords: RNA modification; inflammatory bowel disease RNA modification; inflammatory bowel disease
Show Figures

Figure 1

MDPI and ACS Style

Nakayama, M.; Ozato, Y.; Tsuji, Y.; Arao, Y.; Otsuka, C.; Hamano, Y.; Sumi, G.; Ofusa, K.; Uchida, S.; Vecchione, A.; Ishii, H. RNA Modification in Inflammatory Bowel Diseases. Biomedicines 2022, 10, 1695.

AMA Style

Nakayama M, Ozato Y, Tsuji Y, Arao Y, Otsuka C, Hamano Y, Sumi G, Ofusa K, Uchida S, Vecchione A, Ishii H. RNA Modification in Inflammatory Bowel Diseases. Biomedicines. 2022; 10(7):1695.

Chicago/Turabian Style

Nakayama, Mika, Yuki Ozato, Yoshiko Tsuji, Yasuko Arao, Chihiro Otsuka, Yumiko Hamano, Genzo Sumi, Ken Ofusa, Shizuka Uchida, Andrea Vecchione, and Hideshi Ishii. 2022. "RNA Modification in Inflammatory Bowel Diseases" Biomedicines 10, no. 7: 1695.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop